Sign In
Buy ZURA
$4.31
+0.0750 (+1.77%)
At Close: Jun 23, 2026
Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of “Moderate Buy” by Brokerages
01:12am, Thursday, 29'th Jan 2026
Shares of Zura Bio Limited (NASDAQ: ZURA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. One in
Zura Bio (NASDAQ:ZURA) Trading Up 0.3% – What’s Next?
03:30am, Tuesday, 27'th Jan 2026
Zura Bio Limited (NASDAQ: ZURA - Get Free Report) rose 0.3% on Monday. The company traded as high as $6.57 and last traded at $6.38. Approximately 464,254 shares were traded during mid-day trading, a
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
08:50am, Wednesday, 21'st Jan 2026
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medi
Zura Bio Reports Business Updates and Outlook for 2026
06:30am, Monday, 12'th Jan 2026
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully
Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of “Moderate Buy” by Brokerages
03:44am, Saturday, 15'th Nov 2025
Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
06:30am, Thursday, 13'th Nov 2025
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-path
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
06:30am, Wednesday, 20'th Aug 2025
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-path
Zura Bio price target lowered to $2 from $3 at H.C. Wainwright
06:12am, Tuesday, 19'th Aug 2025
H.C. Wainwright lowered the firm's price target on Zura Bio to $2 from $3 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q2 report to reflect increases in pote
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
08:15am, Thursday, 14'th Aug 2025
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing no
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 17'th Jul 2025
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-path
Zura Bio Announces Chief Financial Officer Transition
06:30am, Tuesday, 01'st Jul 2025
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a
Squarepoint Ops LLC Cuts Stock Position in Zura Bio Limited (NASDAQ:ZURA)
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC lessened its stake in Zura Bio Limited (NASDAQ:ZURA – Free Report) by 48.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange C
Zura Bio to Present at the Jefferies Global Healthcare Conference
06:30am, Tuesday, 27'th May 2025
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-path
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa
06:30am, Tuesday, 20'th May 2025
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSHIELD, a Phase 2 study evaluating tibulizumab in adults with hidradenitis suppurativa.
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates
06:30am, Thursday, 08'th May 2025
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-path
